Cargando…

Concurrent use of Chinese herbal medicine and anticoagulants may reduce major bleeding events

BACKGROUND: This retrospective cohort study investigated the risk of major bleeding events during the concurrent use of Chinese herbal medicine (CHM) and anticoagulants in clinical practice. METHODS: A total of 4,470 patients receiving anticoagulant drugs were selected from Taiwan’s National Health...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Shuo-Min, Lin, Hung-Jen, Kao, Yi-Wei, Li, Te-Mao, Shia, Ben-Chang, Huang, Sheng-Teng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398017/ https://www.ncbi.nlm.nih.gov/pubmed/35998204 http://dx.doi.org/10.1371/journal.pone.0271965

Ejemplares similares

Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants
por: Chang, Kuo-Hsuan, et al.
Publicado: (2022)

Chinese Herbal Medicine Improved Survival in Stage IV Breast Cancer Patients: Data Mining of the Incorporated Taiwan Cancer Registry Database and Hospital Database
por: Chen, Po-En, et al.
Publicado: (2023)

Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants—A nationwide cohort study
por: Wu, Hsin-Hsu, et al.
Publicado: (2022)

Evaluation of Patient Characteristics Linked to Major Bleeding Events in Patients Prescribed Direct Oral Anticoagulants
por: Kanaan, Dareen M., et al.
Publicado: (2023)

Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016
por: Christos, Steve, et al.
Publicado: (2016)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
por: Lecumberri, Ramón, et al.
Publicado: (2021)

Examining the Risks of Major Bleeding Events in Older People Using Antithrombotics
por: Nishtala, Prasad S., et al.
Publicado: (2019)

Impact of Primary Hemostasis Disorders on Late Major Bleeding Events among Anticoagulated Atrial Fibrillation Patients Treated by TAVR
por: Dietrich, Laurent, et al.
Publicado: (2021)

Reversal agents for oral anticoagulant-associated major or life-threatening bleeding
por: Moia, Marco, et al.
Publicado: (2019)

Heparin: Major bleeding event: case report
Publicado: (2021)

This Article Corrects: “Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016”
por: Christos, Steve, et al.
Publicado: (2016)

Correction to: Reversal agents for oral anticoagulant-associated major or life-threatening bleeding
por: Moia, Marco, et al.
Publicado: (2019)

Prothrombin complex concentrate in the management of major bleeding induced by oral anticoagulant therapy
por: AlSheef, Mohammed, et al.
Publicado: (2022)

Major Bleeding Risk in Atrial Fibrillation Patients Co-Medicated With Non-Vitamin K Oral Anticoagulants and Antipsychotics
por: Chen, Chiung-Mei, et al.
Publicado: (2022)

Immunomodulatory Effect of Chinese Herbal Medicine Formula Sheng-Fei-Yu-Chuan-Tang in Lipopolysaccharide-Induced Acute Lung Injury Mice
por: Lin, Chia-Hung, et al.
Publicado: (2013)

Increased Bleeding Risk in a Patient with Oral Anticoagulant Therapy and Concomitant Herbal Intake – A Case Report
por: Gressenberger, Paul, et al.
Publicado: (2019)

Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients
por: Gabara, C., et al.
Publicado: (2023)

Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
por: Wallvik, Niklas, et al.
Publicado: (2020)

Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients
por: Gabara, C., et al.
Publicado: (2023)

Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events
por: Poénou, Géraldine, et al.
Publicado: (2023)

Thrombotic Risk after a Major Bleeding During Anticoagulation: A Clinical Case
por: Conti, Serenella, et al.
Publicado: (2017)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

Impact of anemia on major bleeding in patients taking oral anticoagulants for nonvalvular atrial fibrillation
por: Kinjo, Norito, et al.
Publicado: (2023)

Empiric Anticoagulation Therapy in Hospitalized COVID-19 Patients: An Evaluation of Bleeding Risk Scores Performances in Predicting Bleeding Events
por: Abdelrahman, Mona A., et al.
Publicado: (2022)

A Review of Potential Harmful Interactions between Anticoagulant/Antiplatelet Agents and Chinese Herbal Medicines
por: Tsai, Hsin-Hui, et al.
Publicado: (2013)

Major bleeding risk with non‐vitamin K antagonist oral anticoagulant vs. aspirin in heart failure: network meta‐analysis
por: Huang, Wen‐Yi, et al.
Publicado: (2020)

The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
por: Fang, Jing-Hung, et al.
Publicado: (2021)

The Chinese Herbal Medicine Formula Sheng-Fei-Yu-Chuan-Tang Suppresses Th2 Responses and Increases IFNγ in Dermatophagoides pteronyssinus Induced Chronic Asthmatic Mice
por: Lin, Chia-Hung, et al.
Publicado: (2013)

Performance of the ABC-bleeding risk score for assessing major bleeding risk in Chinese patients with atrial fibrillation on oral anticoagulation therapy: A real-world study
por: Wang, Yu-Feng, et al.
Publicado: (2022)

Uncertain Associations of Major Bleeding and Concurrent Use of Antiplatelet Agents and Chinese Medications: A Nested Case-Crossover Study
por: Tsai, Hsin-Hui, et al.
Publicado: (2017)

Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS‐BLED and GARFIELD‐AF Bleeding Scores
por: Proietti, Marco, et al.
Publicado: (2018)

Serial changes in the trends of direct oral anticoagulant use and incidence of thromboembolisms and major bleeding events in very old patients with non-valvular atrial fibrillation
por: Takahashi, Masahiko, et al.
Publicado: (2023)

Prediction of major bleeding events in 1381 patients with essential thrombocythemia
por: Stuckey, Ruth, et al.
Publicado: (2023)

Understanding Bleeding Risk after Anticoagulation
Publicado: (2005)

Major Thrombotic Event Despite Anticoagulation in a Patient With COVID-19
por: Ataallah, Basma, et al.
Publicado: (2020)

Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis
por: Skaistis, Joel, et al.
Publicado: (2015)

Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients
por: Milling, Truman J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8eh4bc0ibcljbkss0ldvam287o